Evidence map›Paper›PMID 33340242›Full record

ArticleClinical and translational science2021

Human Induced Pluripotent Stem Cell Derived Sensory Neurons are Sensitive to the Neurotoxic Effects of Paclitaxel.

Chenling Xiong, Katherina C Chua, Tore B Stage, Josefina Priotti, Jeffrey Kim, Anne Altman-Merino, Daniel Chan, Krishna Saraf, Amanda Canato Ferracini, Faranak Fattahi and 1 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 3 countries.

Chenling XiongDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Katherina C ChuaDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Tore B StageDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Josefina PriottiDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Jeffrey KimDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Anne Altman-MerinoDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Daniel ChanDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Krishna SarafDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Amanda Canato FerraciniDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Faranak FattahiDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, California, USA.
Deanna L KroetzDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
University of California, San Francisco · USUniversity of Southern Denmark · DK

Funding

PHARMACEUTICAL SCIENCES AND PHARMACOGENOMICST32GM007175 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, KROETZ, DEANNA L · 1985 to 2021
$7.1M
Pharmacogenomics of Microtubule Targeting AgentsR01CA192156 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KROETZ, DEANNA L · 2015 to 2019
$3.8M
NCI NIH HHS R01 CA192156NIGMS NIH HHS T32 GM007175
6 · The paper itself

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse event associated with treatment with paclitaxel and other chemotherapeutic agents. The prevention and treatment of CIPN are limited by a lack of understanding of the molecular mechanisms underlying this toxicity. In the current study, a human induced pluripotent stem cell-derived sensory neuron (iPSC-SN) model was developed for the study of chemotherapy-induced neurotoxicity. The iPSC-SNs express proteins characteristic of nociceptor, mechanoreceptor, and proprioceptor sensory neurons and show Ca

Indexed as

Antineoplastic AgentsCell LineHumansInduced Pluripotent Stem CellsIntravital MicroscopyMembrane Potential, MitochondrialMitochondriaOptical ImagingPaclitaxelPeripheral Nervous System DiseasesSensory Receptor CellsSynaptic PotentialsAntineoplastic AgentsPaclitaxel

Identifiers

PMID33340242
PMCPMC7993321
OpenAlexW3115475789

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.